am 251 has been researched along with Schizophrenia in 7 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively." | 7.91 | Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. ( Babinska, Z; Bari, M; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Giurdanella, G; Iannotti, FA; Maccarrone, M; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2019) |
| "In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively." | 3.91 | Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. ( Babinska, Z; Bari, M; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Giurdanella, G; Iannotti, FA; Maccarrone, M; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2019) |
| "Previous studies have shown that social withdrawal in the phencyclidine (PCP) rat model of schizophrenia results from deficient endocannabinoid-induced activation of CB1 receptors." | 3.83 | Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system. ( Giuffrida, A; Seillier, A, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stark, T | 1 |
| Ruda-Kucerova, J | 1 |
| Iannotti, FA | 1 |
| D'Addario, C | 1 |
| Di Marco, R | 1 |
| Pekarik, V | 1 |
| Drazanova, E | 1 |
| Piscitelli, F | 1 |
| Bari, M | 1 |
| Babinska, Z | 1 |
| Giurdanella, G | 1 |
| Di Bartolomeo, M | 1 |
| Salomone, S | 1 |
| Sulcova, A | 1 |
| Maccarrone, M | 1 |
| Wotjak, CT | 1 |
| Starcuk, Z | 1 |
| Drago, F | 1 |
| Mechoulam, R | 1 |
| Di Marzo, V | 2 |
| Micale, V | 1 |
| Seillier, A | 2 |
| Martinez, AA | 1 |
| Giuffrida, A | 2 |
| Gallo, A | 1 |
| Bouchard, C | 1 |
| Fortier, E | 1 |
| Ducrot, C | 1 |
| Rompré, PP | 1 |
| Kruk-Slomka, M | 1 |
| Budzynska, B | 1 |
| Slomka, T | 1 |
| Banaszkiewicz, I | 1 |
| Biala, G | 1 |
| Guidali, C | 1 |
| Viganò, D | 1 |
| Petrosino, S | 1 |
| Zamberletti, E | 1 |
| Realini, N | 1 |
| Binelli, G | 1 |
| Rubino, T | 1 |
| Parolaro, D | 1 |
| Ballmaier, M | 1 |
| Bortolato, M | 1 |
| Rizzetti, C | 1 |
| Zoli, M | 1 |
| Gessa, G | 1 |
| Heinz, A | 1 |
| Spano, P | 1 |
7 other studies available for am 251 and Schizophrenia
| Article | Year |
|---|---|
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.
Topics: Amides; Animals; Arachidonic Acids; Cannabidiol; Disease Models, Animal; Endocannabinoids; Ethanolam | 2019 |
Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia.
Topics: Amidohydrolases; Amygdala; Animals; Arachidonic Acids; Benzamides; Cannabinoid Receptor Agonists; Ca | 2013 |
Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Benzoxazines; Brain; Brain Injuries; C | 2014 |
Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.
Topics: Analysis of Variance; Animals; Cannabinoid Receptor Modulators; Cyclohexanols; Discrimination, Psych | 2016 |
The Influence of the CB1 Receptor Ligands on the Schizophrenia-Like Effects in Mice Induced by MK-801.
Topics: Animals; Antipsychotic Agents; Cannabinoid Receptor Modulators; Disease Models, Animal; Dizocilpine | 2016 |
Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Modulators; Disease Models, Animal; Excitatory Amino | 2011 |
Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.
Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship | 2007 |